DelveInsight has launched a new report on “Ocular Inflammation and Pain Market“
Ocular Inflammation and Pain is the inflammation of the eye causing pain, it often results from an infection by viruses or bacteria. But inflammation of the eye can also be nonspecific. Ocular inflammation can be caused by a number of different etiological mechanisms. These include allergens, contact lens wear, trauma and dietary or lifestyle changes. While there are different “triggers” of ocular inflammation, they produce similar symptoms because all induce essentially the same immunological cascades. The “irritation” produced is caused by the induction of the interleukin system, immune cell recruitment and complement activation.
Get a free sample page- https://www.delveinsight.com/sample-request/ocular-inflammation-and-pain-market
Ocular Inflammation and Pain Market: Geography Covered
Ocular Inflammation and Pain Key Players
Ocular Inflammation and Pain Drugs
Ocular Inflammation and Pain Treatment
Inflammation after cataract surgery, which can be persistent, remains an undesirable consequence despite many advances in surgical techniques. Although corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) have traditionally been used to treat inflammation, prophylactically as well as post-operatively, there are no established guidelines for the treatment of inflammation induced by cataract surgery. The long-term use of corticosteroids has raised safety concerns, especially with regard to elevated intraocular pressure (IOP).
This limitation of traditional corticosteroids led to the development of C-20 ester corticosteroids through retrometabolic drug design. This design modification allows the corticosteroid to be active at its site of action and then undergo predictable hydrolysis to inactive metabolites, resulting in reduced side effects. While corticosteroids are traditionally the therapy of choice for inflammation, their long-term use for managing ocular inflammation can produce significant adverse events.
Ocular Inflammation and Pain Market Insights
The mainstay of non-infectious uveitis treatment is corticosteroids, which are administered in three forms: topically, locally via sub-Tenon’s or intravitreal injection, and systemically. Immunomodulating drugs may be added to the corticosteroid regimen to eliminate the need for high doses of systemic steroids, or used alone as steroid-sparing agents when steroids are not tolerated. Pharmacological agents used as part of immunomodulatory therapy (IMT) can also have potential adverse events, and thus must be used by physicians who have had extensive experience in administering them.
Primarily, four steroids are available: prednisolone, fluorometholone, dexamethasone and medrysone. On the horizon are two new “soft” steroids that have good anti-inflammatory effect but are metabolized quickly, thus reducing side effects and the likelihood of raising intraocular pressure (IOP).
Ocular Inflammation and Pain Market Size
Expected launch of the pipeline therapies shall fuel the growth of the market during the forecast period, i.e., 2020–2030. The market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase at a CAGR of XX during the study period.
Ocular Inflammation and Pain Report Scope
Table of content
Why should you buy this report?
You can check our latest blogs- https://www.delveinsight.com/blog/
Contact us
Shruti Thakur
[email protected]
+91-9650213330
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/